CN107828871A - The detection reagent that FoxM1 genes P271Q is mutated in Wnt signal paths based on peptide nucleic acid probe - Google Patents
The detection reagent that FoxM1 genes P271Q is mutated in Wnt signal paths based on peptide nucleic acid probe Download PDFInfo
- Publication number
- CN107828871A CN107828871A CN201711188141.0A CN201711188141A CN107828871A CN 107828871 A CN107828871 A CN 107828871A CN 201711188141 A CN201711188141 A CN 201711188141A CN 107828871 A CN107828871 A CN 107828871A
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- peptide nucleic
- foxm1
- primer
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses the detection reagent that FoxM1 genes P271Q in a kind of Wnt signal paths based on peptide nucleic acid probe is mutated, detection reagent has primer and peptide nucleic acid fluorescence probe, primer includes forward and reverse primer, SEQ ID NO.1, NO.3, NO.5, NO.7 in forward primer such as sequence table；SEQ ID NO.2, NO.4, NO.6, NO.8 in reverse primer such as sequence table；SEQ ID NO.9, NO.10, NO.11, NO.12 in the sour fluorescence probe such as sequence table；SEQ ID NO.13, NO.14, NO.15, NO.16 in wild type complementary peptide nucleic acid sequence such as sequence table.Detection method is based on the real time fluorescence quantifying PCR method that peptide nucleic acid PNA is fluorescence probe.The present invention is screening anticancer medicine, and new targeted drug discussion and basic scientific research etc. provide instrument.
Description
The present invention is《The detection reagent of FoxM1 gene mutations, PCR detections in Wnt signal paths based on peptide nucleic acid probe
Method and application》The divisional application of (application number 201510355452.6, the applying date 150624).
Technical field
The invention belongs to molecular biology technical field of biological nucleic acid detection, and in particular to a kind of based on peptide nucleic acid probe
The detection reagent of FoxM1 gene mutations, PCR detection method and application in Wnt signal paths.
Background technology
Wnt signal paths are widely present in invertebrate and vertebrate, are that one kind is high during spore
The conservative signal path of degree.Wnt signals are in the early development of animal embryo, orga- nogenesis, regeneration and other physiology courses
In, there is vital effect.If the key protein in this signal paths is undergone mutation or unconventionality expression, cause letter
Number abnormal activation, it is possible to the generation of induced cancer.Wnt signal paths include classical Wnt signal paths and non-classical Wnt
Signal path, in classical path is Wnt- β-catenin signal paths, the Wnt factors pass through on active cell film
Suppress phosphorylation and the degraded of endocellular liberation β-catenin albumen after Frizzle/LRP5/6 cooperative expert systems, in cytoplasm
The core that β-catenin albumen occurs is shifted after the rise of β-catenin protein levels, causes β-catenin albumen in nucleus
Rise, in karyon β-catenin albumen can combine Pygo2, Bcl-9 and FoxM1 albumen jointly with TCF/LEF-1 transcriptions because
Sub-family forms complex and activates the transcriptional activation of Wnt signal path downstream target genes.
FoxM1 albumen is one of β-catenin downstream important members in Wnt signal paths, at present increasing research
It has been found that in addition to Pygo2 albumen, high expression is also presented in FoxM1 albumen in many tumours.
The core element regulatory mechanism of research core signal path at present, and expression of some important members in cell
Level, have become a kind of key means for the treatment of tumour, although research of the Wnt signal paths in cancer in recent years, and
Research of the FoxM1 albumen as its expression of Wnt signal path important members, have become research and development tumour medicine and be badly in need of
The major issue of solution, but the mutation of its gene in many tumour cells is also more and more simultaneously, to FoxM1 protein exhibits
Function plays very important effect, such as S55C mutation, R256G mutation, dermal melanin are detected in lung adenocarcinoma cell
Detect that P271Q is mutated in oncocyte, the L318F mutation detected in Urothelial Carcinoma of Bladder cell.
Peptide nucleic acid (peptide nucleic acids, PNA) is a kind of DNA for substituting sugared phosphate backbone with polypeptide backbone
Analog.It is on the basis of the first generation, second generation antisense agent, is built by Computer Design and final artificial synthesized
Third generation antisense agent, it is a kind of brand-new DNA analogs, i.e., is substituted with the peptide chain acid amides 2- aminoethylglycines key of neutrality
Pentose phosphate diester linkage skeleton in DNA, remaining is identical with DNA, PNA can pass through Watson-Crick base pairings
Form identifies and combines DNA or RNA sequence, forms stable double-spiral structure.Because PNA is not negatively charged, with DNA and RNA
Between be not present electrostatic repulsion, thus the stability and specificity that combine all greatly improve；Different between DNA or DNA, RNA
Hybridization, PNA and DNA or RNA hybridization are hardly influenceed by hybridization system salinity, remote with the hybridization ability of DNA or RNA molecule
Better than DNA/DNA or DNA/RNA, very high hybridization stability, excellent distinguished sequence recognition capability are shown, not by nuclease
And protease hydrolytic.
The content of the invention
The purpose of the present invention is to be directed to above-mentioned present situation, it is desirable to provide a kind of signal that can determine that core in Wnt signal paths
Molecule FoxM1 gene mutation situations, can explain that core element FoxM1 changes in tumour cell, as a result repeated, and sensitiveness is good
The Wnt signal paths based on peptide nucleic acid probe in FoxM1 genes P271Q be mutated detection reagent.
The implementation of the object of the invention is that FoxM1 genes P271Q dashes forward in the Wnt signal paths based on peptide nucleic acid probe
The detection reagent of change, including primer and probe, the primer include forward primer and reverse primer, and the probe is visited for peptide nucleic acid
Pin；
SEQ ID NO.5 in the detection FoxM1 gene P271Q mutant forward primers such as sequence table；
SEQ ID NO.6 in the detection FoxM1 genes P271Q mutation reverse primers such as sequence table；
SEQ ID NO.11 in the detection FoxM1 genes P271Q mutation PNA fluorescence probes such as sequence table.
The 5' ends and 3' ends of the peptide nucleic acid fluorescence probe are modified with fluorescent reporter group and quenching group respectively, modify institute
The fluorescent reporter group for stating 5' ends is：FAM, HEX, TET, JOE, VIC, ROX, Cy3 or Cy5, that modifies the 3' ends is quenched base
Roll into a ball and be：TAMRA, Eclipse, BHQ1, BHQ2, BHQ3 or DABCYL.
The method that the detection reagent of FoxM1 gene mutations is detected in Wnt signal paths based on peptide nucleic acid probe, inspection
Survey method is based on the real time fluorescence quantifying PCR method that peptide nucleic acid is fluorescence probe；
The reaction system of the real-time fluorescence quantitative PCR is：Forward primer, reverse primer, DEPC water, have 5' → 3' outside
Cut activity archaeal dna polymerase, dNTPs, 10 × PCR Buffer, RNASIN, M-MLV reverse transcriptase, oligo (dT) and containing Mg from
The solution of son；
The archaeal dna polymerase exo-acting with 5' → 3' is Taq enzyme.
The application of the detection reagent of FoxM1 gene mutations in Wnt signal paths based on peptide nucleic acid probe, examined for preparing
The detection reagent of tumour cell and normal cell is surveyed, the cancer cell is lung adenocarcinoma cell, dermal melanin oncocyte or bladder
Urothelial cell.
The present invention is using the PNA oligomers of distinguished sequence as probe.Because PNA is a kind of class of artificial synthesized nucleic acid
Like thing, and it is achirality, uncharged molecule, avoids when oligonucleotides is combined with its target gene because electric charge is mutually exclusive
Caused hybridization unstability, with reference to being not easy to be influenceed by hybridization solution ionic strength, so as to show extremely strong heterosis, hybrid vigor,
Substantially increase detection sensitivity.
Compared with prior art, the advantages and positive effects of the present invention are:FoxM1 genes are that newfound Wnt signals lead to
The gene for playing critical function of β-catenin proteins downstreams in road, the invention provides directly detect in Wnt signal paths
The reagent of FoxM1 detection in Gene Mutation, can be by quantitative real-time PCR in transcriptional level by means of the detection reagent
Quick detection goes out the mutation of FoxM1 genes, and unlike common real-time fluorescence quantitative PCR, the peptide nucleic acid PNA that we use
Fluorescence probe is sensitiveer, and the present invention is the screening of cancer therapy drug, and the Mechanism Study of new targeted drug both provides very strong
Instrument.
Brief description of the drawings
Fig. 1 is peptide nucleic acid mass spectrogram described in the embodiment of the present invention；
Fig. 2 is S55C saltant types described in the embodiment of the present invention and reference wild-type product PCR amplification figures；
Fig. 3 is R256G saltant types described in the embodiment of the present invention and reference wild-type product PCR amplification figures；
Fig. 4 is P271Q saltant types described in the embodiment of the present invention and reference wild-type product PCR amplification figures；
Fig. 5 is L318F saltant types described in the embodiment of the present invention and reference wild-type product PCR amplification figures.
Embodiment
The detection reagent of Pygo2 gene mutations in Wnt signal paths based on peptide nucleic acid probe, the primer include forward direction
Primer and reverse primer, the probe are peptide nucleic acid probe, it is characterised in that：
SEQ ID NO.5 in the detection FoxM1 gene P271Q mutant forward primers such as sequence table；
SEQ ID NO.6 in the detection FoxM1 genes P271Q mutation reverse primers such as sequence table；
SEQ ID NO.11 in the detection FoxM1 genes P271Q mutation PNA fluorescence probes such as sequence table.
The 5' ends and 3' ends of the peptide nucleic acid fluorescence probe are modified with fluorescent reporter group and quenching group respectively, modify institute
The fluorescent reporter group for stating 5' ends is：FAM, HEX, TET, JOE, VIC, ROX, Cy3 or Cy5, that modifies the 3' ends is quenched base
Roll into a ball and be：TAMRA, Eclipse, BHQ1, BHQ2, BHQ3 or DABCYL.
Detection reagent also contains contrast agent, and contrast agent is the peptide nucleic acid sequence complementary with FoxM1 genes wild type,
The specific binding includes SEQ ID in the codon wild type PNA sequences of FoxM1 genes 271 such as sequence table
NO.15。
The mass spectrogram of peptide nucleic acid used in the present invention is shown in Fig. 1.
The method detected with the detection reagent of FoxM1 gene mutations in the Wnt signal paths based on peptide nucleic acid probe,
Detection method is PCR detection method, and the PCR detection method is based on the real-time fluorescence quantitative PCR that peptide nucleic acid is fluorescence probe
Method；
The reaction system of the real-time fluorescence quantitative PCR is：Forward primer, reverse primer, DEPC water, have 5' → 3' outside
Cut activity archaeal dna polymerase, dNTPs, 10 × PCR Buffer, RNASIN, M-MLV reverse transcriptase, oligo (dT) and containing Mg from
The solution of son.
The archaeal dna polymerase exo-acting with 5' → 3' is Taq enzyme.
The detection method of FoxM1 gene mutations, detecting step are as follows in Wnt signal paths based on peptide nucleic acid probe：
1) primer and PNA in these sites are detected for the design of the codon mutation type of FoxM1 genes 55,256,271,318
Probe；
2) 4 sections for the design of the Codon sequences of FoxM1 genes 55,256,271,318 with these site wild types complementations
PNA sequences；
3) plasmid containing FoxM1 genic mutation types and wild type is built, and calculates copy number, reference material is made；
4) mRNA in cell to be measured is extracted；
5) fluorescence quantitative PCR detection is carried out to reference material and sample with above-mentioned detection FoxM1 gene mutations reagent, and judged
Whether the codon of FoxM1 genes 55,256,271,318 undergos mutation.
Final concentration of 0.01U/ μ L~0.05U/ μ L of Taq enzyme described in the PCR reaction solutions, the end of the dNTPs are dense
Spend for 0.2~0.6mM, 10 × PCR Buffer final concentration of 1 ×, the final concentration of 40U/ μ L of the RNASIN~
60U/ μ L, final concentration of 200U/ μ L~320U/ μ L, the MgCl of the M-MLV reverse transcriptases2Final concentration of 1.5~
5.0mM, solvent are DEPC water, final concentration of 0.05~0.9 μM of the forward primer, the reverse primer it is final concentration of
0.05~0.9 μM, final concentration of 0.05~0.9 μM of the fluorescence probe.
The response procedures of the real-time fluorescence quantitative PCR are：42 DEG C of reverse transcription 20min；94 DEG C of pre-degenerations, 2min；95℃
Denaturation, 30s；58 DEG C, 45s；Carry out 40 circulations.
The experimental system of the present invention can be carried out on any real-time fluorescence quantitative PCR instrument, its PCR reaction kit
For the type quantitative real time PCR Instrument of Applied Biosystems companies 7500.Above-mentioned primer is placed in eight unions, carries out real-time fluorescence
Quantitative PCR detection, experimental implementation is simple, low-cost, and as a result repeated, sensitiveness is good, is the related drugs effect of research tumour
A kind of important means of mechanism and basic scientific research.
The detection reagent of Pygo2 gene mutations is used to prepare detection tumour in Wnt signal paths based on peptide nucleic acid probe
The detection reagent of cell and normal cell, the cancer cell are on lung adenocarcinoma cell, dermal melanin oncocyte or bladder urinary tract
Chrotoplast.
The present invention is illustrated by pancreatic cancer cell.
PNAC-1 (human pancreas cancer PNAC-1 cell lines) cell line is purchased from U.S. ATCC in the present invention, and culture cell is used
RPMI-1640 culture mediums and 10% hyclone be purchased from handsome company, other reagents are mainly (big purchased from precious bioengineering
Even) Co., Ltd.
Detecting intracellular Wnt signal paths Pygo2 gene mutations using reagent of the present invention includes step in detail below：
According to American National Biotechnology Information center (National Center for Biotechnology
Information, NCBI) (http://www.ncbi.nlm.nih.gov) report hFoxM1mRNA sequences (NCBI
Reference Sequence:NM_202002.2), the Primer developed using Applied Biosystems companies
Express Software for Real-Time PCR Software for Design special FoxM1 primers and probe.
FoxM1P271Q：
FoxM1-F:5'-GACATCTATACGTGGATTGAGGACC-3'；
FoxM1-R:5'-GAGACCTTGCCATTGGCAGA-3'；
FoxM1(PNA)-P:5'FAM-TTTCAATACTTTAAGCACATTGCC-BHQ 3'；
FoxM1-PNA：TTTCCCTACTTTAAGCACATTGCC
Target sequence：
GAAAGACATCTATACGTGGATTGAGGACCACTTTCCCTACTTTAAGCACATTGCCAAGCCAGGCTGGAAGAACTCCA
TCCGCCACAACCTTTCCCTGCACG ACATGTTTGTCCGGGAGACGTCTGCCAATGGCAAGGTCTCCTT
More than：F：Forward, it is positive；HW-F represents the forward primer for detecting hookworm nucleic acid.
R：Reverse, reversely；HW-R represents the reverse primer for detecting hookworm nucleic acid.
P：Probe, fluorescence probe；HW-P represents the fluorescence probe for detecting hookworm nucleic acid, and the fluorescence probe is
TaqMan fluorescence probes.
In embodiments of the present invention, modifying the fluorescent reporter group at the 5' ends of fluorescence probe can be：FAM, HEX, TET,
JOE, VIC, ROX, Cy3 or Cy5；Modifying the quenching group at the 3' ends of fluorescence probe can be：TAMRA, Eclipse, BHQ1,
BHQ2, BHQ3 or DABCYL, the fluorescent reporter group do not influence the amplification of quantitative fluorescent PCR with quenching group, only need to be according to spy
The model of instrument used in fluorescent reporter group and the quenching group selection of pin sets detectable fluorescence signal scope.The present invention
The fluorescence probe fluorescent reporter group that embodiment provides：FAM, HEX, TET and FAM excitation wavelength are 470-650nm, received wave
A length of 500-700nm；Quenching group：Eclipse、TAMRA、BHQ1.Primer synthesis after way of purification can be：HAP、PAGE
With HPLC way of purification.
2nd, the culture of human lung adenocarcinoma Calu-3 cell lines and passage
1) cell culture
All cell lines use RPMI-1640 culture mediums (Invitrogen, Carlsbad, CA), 10% hyclone
(Invitrogen, Carlsbad, CA), in 37 DEG C, 5%CO2Cultivated under environment.
2) passage
The nutrient solution in Tissue Culture Dish is suctioned out first by sterilized straw, PBS is added and cleans 2 times, toward carefully
Appropriate trypsase is slowly added dropwise in born of the same parents, treats that cell rounding, adjustment angle cell add 3ml and contain 10% tire ox after can moving
The DMEM culture mediums of serum, after gently blowing and beating repeatedly, micro- Microscopic observation cellular morphology simultaneously counts, according to cell in culture dish
In the culture dish that content sterilizes appropriate passage to other, 5%CO is put into after adding 5ml DMEM culture mediums2Culture
Case.
Cell count formula (individual/ml)：(4 big lattice TCS) × 104× extension rate/4
3rd, the extraction of total serum IgE
1) outwell culture medium, after PBS, 1ml Trizol are directly injected into blake bottle (wherein cell 5 × 106Individual/
Ml), suction is uniform repeatedly；
2) 0.2ml chloroform (for the 1/5 of Trizol cumulative volumes) is added in the centrifuge tube equipped with lysate, vibration is mixed
30 seconds, stand 5 minutes at room temperature；
3) 4 DEG C of 12000rpm is centrifuged 15 minutes, and split-phase is three layers.Upper strata：RNA (about the 60% of Trizol)；It is middle：
DNA；Lower floor:Protein (phenol-chloroform)；
4) careful Aspirate supernatant, it is transferred in another EP pipes.Supernatant volume caused by 1ml lysates is about 0.4~
0.6ml.DNA and protein are contained in organic phase and intermediate layer, avoid touching；
5) supernatant adds about 0.5ml isopropanol, and vibration is mixed 30 seconds.Stand 10 minutes at room temperature；
6) 4 DEG C of 12000rpm is centrifuged 10 minutes；
7) RNA precipitate will be formed in the side at centrifugation bottom.Careful inhale abandons supernatant, pays attention to avoiding suction from abandoning RNA precipitate；
8) centrifuge tube adds 75% ethanol (1ml Trizol at least 1ml ethanol cleaning DNA) of 1ml precoolings, and vibration is mixed
30 seconds, vibrate precipitation, room temperature 12000rpm is centrifuged 1~2 minute.Inhale as far as possible and abandon supernatant, prevent RNA precipitate from losing
Lose.Repeat above cleaning step once.In 75% ethanol, RNA is at least preserved 1 week at 4 DEG C, and -20 DEG C at least preserve 1 year；
9) room temperature selecting liquidity is small, is inverted centrifuge tube on filter paper, dries RNA, but can not be completely dried (5~10 points
Clock).Dissolved and precipitated with the μ L of DEPC water 15,55-60 DEG C is incubated 10~15 minutes.
10) RNA purity detectings
2 μ L RNA solutions are added dropwise in ultramicrospectrophotometer (model：P330-311), and OD260/ in instrument is read
OD280 ratios.
4th, construction recombination plasmid
1) DNA fragmentation containing FoxM1 genic mutation types and wild type is entered into performing PCR amplification；
2) PCR primer is subjected to double digestion；
Carrier and PCR primer carry out double digestion with condition once respectively, and (reaction system is 30ul, and 37 DEG C, digestion 2 is small
When)；
3) by rubber tapping recovery (being operated according to kit specification) after double digestion product electrophoresis；
4) digestion products and plasmid vector are attached；
Above-mentioned double digestion product is by purifying (wherein carrier digestion products rubber tapping recovery, purification step after PCR fragment digestion
It is identical with above-mentioned PCR primer purification step), 16 DEG C connect overnight under T4DNA connection enzyme effects.Linked system is as follows：Carrier,
2ul；PCR fragment, 6ul；10xT4buffer, 1ul；T4DNA ligase, 1ul.
5) E. coli competent is converted；
The above-mentioned μ l of connection liquid 5 are taken to be transformed into previously prepared DH5 α Competent cells, ice bath 30 minutes, 42 DEG C of heat
Swash 2min, put 5min on ice, add 1mlLB 37 DEG C of shaking table 45min of nutrient solution, centrifuge 5000rpm, 1-5min (not centrifuged too
Long, it is in order to avoid too real), finally it is uniformly coated on (100-150ul) on the LB flat boards containing 100ng/ml antibiotic.By flat board 37
DEG C be inverted overnight incubation.Picking positive colony bacterium colony turns to draw onto another piece of LB flat board containing 100ng/ml antibiotic, and right
Be numbered, 37 DEG C inversion overnight incubations.
6) QIAGEN kits extracting plasmid (carrying out to specifications), is made reference material.
5th, real-time fluorescence quantitative PCR
The total serum IgE 1-5 μ g of extraction are taken, add PCR reaction solutions, PCR reaction solutions include：Sterilized water, have 5' → 3' circumscribed
Archaeal dna polymerase, dNTPs, 10 × PCR Buffer, RNASIN, M-MLV reverse transcriptase, oligo (dT) and the ion containing Mg of activity
Solution.Wherein, the archaeal dna polymerase 0.3 μ L exo-acting with 5' → 3' that concentration is 5U/ μ L, concentration are 10mmol/L's
The μ L of 2 μ L, 10 × PCR Buffer of dNTPs 5, concentration are the 40U/ μ L μ L of RNASIN 0.6, and concentration is 200U/ μ L M-MLV
The μ L of reverse transcriptase 0.6, concentration are 25mmol/L MgCl2The μ L of solution 5, addition sterilized water to volume is 50 μ L.Wherein, there is 5'
Archaeal dna polymerase exo-acting → 3' can be Taq enzyme.
PCR is expanded：Each reaction tube is put into the reactive tank of quantitative fluorescent PCR instrument, setting mark fluorescent radical species,
Sample ID and type, (this product fluorescent reporter group is FAM, HEX, TAT to the Taqman fluorescence probe of selection, fluorescence
Quenching group is Eclipse), sample well is defined, and the amplification program that according to the form below provides enters performing PCR amplification：
The pcr amplification reaction amplification program of table 1
Fluorescent value is read in the end of a period of the 3rd step of amplification program.
P271Q saltant types described in the embodiment of the present invention and reference wild-type product PCR amplification figures are shown in Fig. 4；It is upper in figure, in,
Lower three bars of lines respectively represent the amplification curve of the bit codon mutation type reference materials of FoxM1 the 271st, sample and reference wild-type product.
The 55th, 256 bit codons are saltant type in adenocarcinoma of lung Calu-3 cell lines as seen from the figure, and the 271st, 318 bit codons are equal
For wild type.
6th, data analysis judges：
Selected institute's sample sheet saltant type corresponding with the pattern detection site and reference wild-type sample wells simultaneously, contrast three holes
PCR amplification curves (CTARepresent sample aperture CT values, CTWRepresent wild type CT values, CTMRepresent saltant type CT values)：
Work as CTW＜ CTA≤CTMWhen, show that the sample has mutation；
Work as CTW=CTAWhen, it is wild type to show the sample.
Sequence table
<110>Hubei University Of Technology
<120>The detection reagent that FoxM1 genes P271Q is mutated in Wnt signal paths based on peptide nucleic acid probe
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 25
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 1
gacatctata cgtggattga ggacc 25
<210> 2
<211> 20
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 2
gagaccttgc cattggcaga 20
<210> 3
<211> 24
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 3
tttcaatact ttaagcacat tgcc 24
<210> 4
<211> 24
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 4
tttccctact ttaagcacat tgcc 24
Claims (2)
1. the detection reagent that FoxM1 genes P271Q is mutated in the Wnt signal paths based on peptide nucleic acid probe, including primer and spy
Pin, the primer include forward primer and reverse primer, and the probe is peptide nucleic acid probe, it is characterised in that：
SEQ ID NO.5 in the detection FoxM1 gene P271Q mutant forward primers such as sequence table；
SEQ ID NO.6 in the detection FoxM1 genes P271Q mutation reverse primers such as sequence table；
SEQ ID NO.11 in the detection FoxM1 genes P271Q mutation PNA fluorescence probes such as sequence table；
The 5' ends and 3' ends of the peptide nucleic acid fluorescence probe are modified with fluorescent reporter group and quenching group respectively, modify the 5'
The fluorescent reporter group at end is：FAM, HEX, TET, JOE, VIC, ROX, Cy3 or Cy5, the quenching group for modifying the 3' ends are：
TAMRA, Eclipse, BHQ1, BHQ2, BHQ3 or DABCYL.
2. the inspection that FoxM1 genes P271Q is mutated in the Wnt signal paths according to claim 1 based on peptide nucleic acid probe
Test agent, it is characterised in that：Detection reagent also contains contrast agent, and contrast agent is the peptide complementary with FoxM1 genes wild type
Nucleotide sequence, the specific binding include SEQ ID in the codon wild type PNA sequences of FoxM1 genes 271 such as sequence table
NO.15。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711188141.0A CN107828871A (en) | 2015-06-24 | 2015-06-24 | The detection reagent that FoxM1 genes P271Q is mutated in Wnt signal paths based on peptide nucleic acid probe |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510355452.6A CN105039522A (en) | 2015-06-24 | 2015-06-24 | Detection reagent based on FoxM1 gene mutations in Wnt signal paths of peptide nucleic acid probes, PCR detection method and application of detection reagent |
| CN201711188141.0A CN107828871A (en) | 2015-06-24 | 2015-06-24 | The detection reagent that FoxM1 genes P271Q is mutated in Wnt signal paths based on peptide nucleic acid probe |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510355452.6A Division CN105039522A (en) | 2015-06-24 | 2015-06-24 | Detection reagent based on FoxM1 gene mutations in Wnt signal paths of peptide nucleic acid probes, PCR detection method and application of detection reagent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107828871A true CN107828871A (en) | 2018-03-23 |
Family
ID=54446488
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510355452.6A Pending CN105039522A (en) | 2015-06-24 | 2015-06-24 | Detection reagent based on FoxM1 gene mutations in Wnt signal paths of peptide nucleic acid probes, PCR detection method and application of detection reagent |
| CN201711188141.0A Pending CN107828871A (en) | 2015-06-24 | 2015-06-24 | The detection reagent that FoxM1 genes P271Q is mutated in Wnt signal paths based on peptide nucleic acid probe |
| CN201711188151.4A Pending CN107893105A (en) | 2015-06-24 | 2015-06-24 | The detection reagent that FoxM1 genes R256G is mutated in Wnt signal paths based on peptide nucleic acid probe |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510355452.6A Pending CN105039522A (en) | 2015-06-24 | 2015-06-24 | Detection reagent based on FoxM1 gene mutations in Wnt signal paths of peptide nucleic acid probes, PCR detection method and application of detection reagent |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711188151.4A Pending CN107893105A (en) | 2015-06-24 | 2015-06-24 | The detection reagent that FoxM1 genes R256G is mutated in Wnt signal paths based on peptide nucleic acid probe |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN105039522A (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106319068A (en) * | 2016-09-28 | 2017-01-11 | 湖北工业大学 | Reagent for Chibby homologue 1 gene mutation detection and application |
| CN109321578A (en) * | 2018-08-31 | 2019-02-12 | 南通大学附属医院 | FOXM1 gene, kit for detecting it and application thereof |
| CN113005179B (en) * | 2021-02-26 | 2021-11-16 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | Mass spectrum method for quantifying nucleic acid based on DNA-polypeptide probe technology and application |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977052A (en) * | 2004-03-23 | 2007-06-06 | 肿瘤疗法科学股份有限公司 | Method for diagnosing non-small cell lung cancer |
| WO2010100899A1 (en) * | 2009-03-02 | 2010-09-10 | 株式会社ジーンサイエンス | Genetic testing method for cancer by analysis of expression of cancer-relating gene utilizing monocyte contained in blood sample |
| US20140024539A1 (en) * | 2011-02-02 | 2014-01-23 | Translational Genomics Research Institute | Biomarkers and methods of use thereof |
| WO2015024876A2 (en) * | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Screening method |
| WO2015068957A1 (en) * | 2013-11-11 | 2015-05-14 | Panagene Inc. | Method for the detection of multiple target nucleic acids using clamping probes and detection probes |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7875275B2 (en) * | 2004-06-16 | 2011-01-25 | The General Hospital Corporation | Use of Bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes |
| CN101974069A (en) * | 2010-10-22 | 2011-02-16 | 西南交通大学 | High-efficiency binding peptide in DNA binding region protein of FoxM1c and method for acquiring polypeptide structure sequence |
-
2015
- 2015-06-24 CN CN201510355452.6A patent/CN105039522A/en active Pending
- 2015-06-24 CN CN201711188141.0A patent/CN107828871A/en active Pending
- 2015-06-24 CN CN201711188151.4A patent/CN107893105A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1977052A (en) * | 2004-03-23 | 2007-06-06 | 肿瘤疗法科学股份有限公司 | Method for diagnosing non-small cell lung cancer |
| WO2010100899A1 (en) * | 2009-03-02 | 2010-09-10 | 株式会社ジーンサイエンス | Genetic testing method for cancer by analysis of expression of cancer-relating gene utilizing monocyte contained in blood sample |
| US20140024539A1 (en) * | 2011-02-02 | 2014-01-23 | Translational Genomics Research Institute | Biomarkers and methods of use thereof |
| WO2015024876A2 (en) * | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Screening method |
| WO2015068957A1 (en) * | 2013-11-11 | 2015-05-14 | Panagene Inc. | Method for the detection of multiple target nucleic acids using clamping probes and detection probes |
Non-Patent Citations (2)
| Title |
|---|
| DAVID BALLI等: ""Endothelial Cell-specific Deletion of Transcription Factor FOXM1 Increases Urethane-induced Lung Carcinogenesis"", 《CANCER RES》 * |
| MARCIN IMIELINSKI 等: ""Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing"", 《CELL》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107893105A (en) | 2018-04-10 |
| CN105039522A (en) | 2015-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104911268B (en) | Detection reagent, PCR detection method and the application of Pygo2 gene mutation in Wnt signal path based on peptide nucleic acid probe | |
| CN107630092B (en) | Application of miR-505-3p in diagnosis, prognosis and treatment of bone metastasis of prostate cancer | |
| CN107881241A (en) | Application of the gene marker in breast cancer diagnosis and treatment | |
| CN106701900A (en) | Long-chain noncoding RNA HERC2P3 gene and application thereof in gastric cancer | |
| CN105821127A (en) | Adenomatous polyposis coli protein APC gene mutation detection reagent and application thereof | |
| CN105838796A (en) | AXIN2 gene mutation detection reagent and application | |
| CN107828871A (en) | The detection reagent that FoxM1 genes P271Q is mutated in Wnt signal paths based on peptide nucleic acid probe | |
| CN107828873A (en) | The detection reagent that the gene P546R of Bcl 9 are mutated in Wnt signal paths based on peptide nucleic acid probe | |
| CN104911271A (en) | Detection reagent based on Pygo2 and FoxM1 gene expression in Wnt signal pathways of peptide nucleic acid probes, PCR detection method and application of detection reagent | |
| CN105950720A (en) | Beta-catenin gene mutation detection reagent in Wnt signal path and applications of beta-catenin gene mutation detection reagent | |
| CN107893115B (en) | ALKBH1 gene and application of expression product thereof in preparation of kit for diagnosing tumors and drugs for treating tumors | |
| CN106244715A (en) | The reagent of a kind of β catenin interaction protein 1 gene abrupt climatic change and application | |
| CN105713986A (en) | Reagent used for detecting glycogen synthase kinase 3beta (GSK3beta) gene mutation and application | |
| CN105713985B (en) | A kind of reagent and application for plug transcription factor O1 detection in Gene Mutation | |
| CN107267616A (en) | A kind of application of Noncoding gene biomarker in liver cancer | |
| CN104774966B (en) | Adenocarcinoma of lung miRNA labels | |
| CN110452989A (en) | Application of the biomarker in gastric cancer is detected, diagnosed | |
| CN108192977A (en) | A kind of and relevant molecular marker of gastric cancer occurrence and development | |
| CN105695619A (en) | Casein kinase-1 gene mutation detection reagent based on peptide nucleic acid probes and application | |
| CN105441405A (en) | A BMX spliceosome and applications thereof in lung cancer drug resistance | |
| CN108707672A (en) | Applications of the DUXAP8 in diagnosis of hepatoma and treatment | |
| CN106520776A (en) | Breast cancer screening kit | |
| CN110241224B (en) | Use of lncRNA-T065925, kit for diagnosing colorectal cancer and medicament for treating colorectal cancer | |
| CN106995857A (en) | Applications of the biomarker ENSG00000267416 in cancer | |
| CN106367517A (en) | Low-density lipoprotein receptor-related protein 5 (LRP5) gene mutation detection reagents and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180323 |
|
| RJ01 | Rejection of invention patent application after publication |